Phenotypes associated with this allele

• Allele Symbol: Tnfaip3^tm1Homy
• Allele Name: targeted mutation 1, Hiroaki Honda
• Allele ID: MGI:5621002
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm9(cre/ESR1)Arte/? Tnfaip3^tm1Homy/Tnfaip3^tm1Homy	involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac	MGI:5698269
cn2	Tnfaip3^tm1Homy/Tnfaip3^tm1Homy Tg(Mx1-cre)1Cgn/?	involves: 129S6/SvEvTac * C57BL/6J * CBA/J	MGI:5698264

Genotype
MGI:5698269

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/?; Tnfaip3^tm1Homy/Tnfaip3^tm1Homy
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Microemboli and necrotic areas in Tnfaip3^tm1Homy/Tnfaip3^tm1Homy Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/? liver

hematopoietic system

hematopoietic system phenotype ( J:212681 )

N • no spontaneous development of abnormal phenotype

thymus atrophy ( J:212681 )

abnormal blood cell morphology/development ( J:212681 )

• marked drop in hematopoietic cell after tamoxifen administration

pale spleen ( J:212681 )

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:212681 )

• die within several days of tamoxifen administration

liver/biliary system

abnormal liver morphology ( J:212681 , J:212681 )

• microembolic and necrotic areas in the liver after tamoxifen administration (J:212681)

• with white spots after tamoxifen administration (J:212681)

cellular

increased apoptosis ( J:212681 )

• massive apoptosis in major organs after tamoxifen administration

immune system

thymus atrophy ( J:212681 )

pale spleen ( J:212681 )

abnormal circulating cytokine level ( J:212681 )

• elevated levels of GM-CSF after tamoxifen administration

increased circulating interferon-gamma level ( J:212681 )

• particularly elevated after tamoxifen administration

abnormal circulating interleukin level ( J:212681 )

increased circulating interleukin-1 beta level ( J:212681 )

• elevated after tamoxifen administration

increased circulating interleukin-6 level ( J:212681 )

• particularly elevated after tamoxifen administration

increased circulating tumor necrosis factor level ( J:212681 )

• particularly elevated TNF-alpha levels after tamoxifen administration

homeostasis/metabolism

abnormal circulating cytokine level ( J:212681 )

• elevated levels of GM-CSF after tamoxifen administration

increased circulating interferon-gamma level ( J:212681 )

• particularly elevated after tamoxifen administration

abnormal circulating interleukin level ( J:212681 )

increased circulating interleukin-1 beta level ( J:212681 )

• elevated after tamoxifen administration

increased circulating interleukin-6 level ( J:212681 )

• particularly elevated after tamoxifen administration

increased circulating tumor necrosis factor level ( J:212681 )

• particularly elevated TNF-alpha levels after tamoxifen administration

increased susceptibility to xenobiotic induced morbidity/mortality ( J:212681 )

• die within several days of tamoxifen administration

endocrine/exocrine glands

thymus atrophy ( J:212681 )

Genotype
MGI:5698264

cn2

• Allelic Composition: Tnfaip3^tm1Homy/Tnfaip3^tm1Homy; Tg(Mx1-cre)1Cgn/?
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J * CBA/J

Inflammation in the lung and liver and destruction of spleen architecture of Tnfaip3^tm1Homy/Tnfaip3^tm1Homy Tg(Mx1-cre)1Cgn/? mice

growth/size/body

cachexia ( J:212681 )

• spontaneous emaciation and cachexia without stimulation with polyinosinic:polycytidylic acid (pIpC)

enlarged liver ( J:212681 )

mortality/aging

premature death ( J:212681 )

• most mice die within six months of birth

hematopoietic system

hematopoietic system phenotype ( J:212681 )

N • no significant differences in WBC and platelets between homozygotes and controls at 3 and 6 months

abnormal blood cell morphology/development ( J:212681 )

abnormal myelopoiesis ( J:212681 )

• proliferation of myeloid cells

anemia ( J:212681 )

• progressive anemia

abnormal B cell number ( J:212681 )

• reduced B lymphoid cell numbers in peripheral blood

abnormal spleen morphology ( J:212681 )

• destruction of spleen architecture due to proliferation of white blood cells of myeloid origin

immune system

abnormal myelopoiesis ( J:212681 )

• proliferation of myeloid cells

abnormal B cell number ( J:212681 )

• reduced B lymphoid cell numbers in peripheral blood

abnormal spleen morphology ( J:212681 )

• destruction of spleen architecture due to proliferation of white blood cells of myeloid origin

abnormal circulating cytokine level ( J:212681 )

• significantly increased levels of GM-CSF

increased circulating interferon-gamma level ( J:212681 )

• significantly increased

abnormal circulating interleukin level ( J:212681 )

increased circulating interleukin-1 beta level ( J:212681 )

• elevated

increased circulating interleukin-6 level ( J:212681 )

• elevated

increased circulating tumor necrosis factor level ( J:212681 )

• significantly increased TNF-alpha levels

enlarged lymph nodes ( J:212681 )

• swelling of lymph nodes

liver inflammation ( J:212681 )

• infiltration with hematopoietic cells

lung inflammation ( J:212681 )

• infiltration of lungs with hematopoietic cells

liver/biliary system

enlarged liver ( J:212681 )

liver inflammation ( J:212681 )

• infiltration with hematopoietic cells

respiratory system

lung inflammation ( J:212681 )

• infiltration of lungs with hematopoietic cells

homeostasis/metabolism

abnormal circulating cytokine level ( J:212681 )

• significantly increased levels of GM-CSF

increased circulating interferon-gamma level ( J:212681 )

• significantly increased

abnormal circulating interleukin level ( J:212681 )

increased circulating interleukin-1 beta level ( J:212681 )

• elevated

increased circulating interleukin-6 level ( J:212681 )

• elevated

increased circulating tumor necrosis factor level ( J:212681 )

• significantly increased TNF-alpha levels